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Patients with myelodysplastic syndrome who fail hypomethylating agents have a very short median
survival and about 25% risk of disease transformation to acute myeloid leukemia. We report our
experience with low-dose protracted oral clofarabine in one patient who achieved stable disease for
more than two years after failing 5-azacitidine.
& 2013 Elsevier Ltd.Open access under CC BY-NC-ND license.Myelodysplastic syndrome (MDS) is a group of clonal bone
marrow disorders with increased risk for leukemic transformation.
Aside from allogeneic stem cell transplantation, the currently
approved treatments for MDS, including growth factors, lenalido-
mide and hypomethylating agents, are not curative and have short
response duration.1 Further, after failure of hypomethylating
agents, the median survival is very short-lived, only 4.3 months
with similar 25% risk of progression to acute myeloid leukemia,2
by one report. Another large study including 435 patients with
high risk MDS that failed hypomethylating therapy demonstrated
a median overall survival of 5.6 months and a two-year survival
probability of only 15%.3 Of note, lack of hematologic response to
previous hypomethylating therapy was one of the factors asso-
ciated with poor outcome.3 Clofarabine is a second generation
purine nucleoside analog that was tested in MDS both intrave-
nously (IV)4 and orally.5 The IV route (15 mg/m2 vs. 30 mg/m2
daily for ﬁve days every 4–8 weeks) was administered in-house
and was signiﬁcantly myelotoxic. Only a median of two consolida-
tion cycles were administered resulting in a median survival of
7.4 months. Since oral clofarabine has a bioavailability of 50% and
could be administered in the ambulatory setting, it was tested in
three different doses (20, 30 and 40 mg/m2 daily for ﬁve days
every 4–8 weeks). A median of one consolidation cycle was
administered to 31% of the patients with dose reduction in 74%
of them due to infectious complications and prolonged716 845 2343.
Wetzler).
-NC-ND license.myelosuppression. The median survival was 9.2 months. Most
patients received the treatment in the ambulatory setting but 53%
received growth factor support at some point and 50% developed
infectious complications requiring hospitalization.
We hypothesized that protracted low-dose oral clofarabine
will be more efﬁcacious and less toxic and designed a phase I
(I–144208, NCT01003678) trial to determine the safety and
maximum tolerated dose of low-dose oral clofarabine daily for
ﬁve days in a 28-day cycle. The initial dose was 1 mg as a ﬁxed
dose. Eligibility criteria included adult patients with intermediate-
or high-risk MDS per the International Prognostic Scoring System
Score (IPSS) who may have received up to two prior therapies and
had adequate hepatic and renal function. The study was prema-
turely terminated by the company and we report here our
experience with one patient on trial.Case report
A 76 year-old Caucasian male who was evaluated in an emer-
gency department due to headache in May 2001 and was found to
have a right parietal subdural hematoma (SDH). Baseline blood work
revealed thrombocytopenia of 50109/L. His SDH was managed
with surgical evacuation with full recovery. He was then referred to
our institute for evaluation of persistent thrombocytopenia in August
2001 after recovering from a second SDH that was managed
expectantly. His past medical history was limited to hypertension;
he was a former smoker and he denied any chemical exposures,
allergies or relevant family history. His initial white blood cell (WBC)
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hemoglobin 10.2 g/dL and platelets 51109/L. His anemia work-up,
thyroid, liver and renal functions were within normal range. Anti-
nuclear antibodies, hemolysis workup and disseminated intravascu-
lar coagulation panel were also negative. A bone marrow biopsy and
aspirate showed refractory cytopenia with multilineage dysplasia
(RCMD), cellularity of 60% and 2.8% blasts with normal karyotype
rendering him an IPSS of 0. The patient was observed until March
2003 without requiring any blood products; however his platelet
counts gradually deteriorated to 25109/L. A repeated bone marrow
biopsy and aspirate on 03/08/2003 showed refractory anemia with
an excess of blasts -1 with trilineage dysplasia, cellularity 65%,
blasts 6.5% and normal male karyotype. It was mutually decided to
continue observing until he was placed on erythropoietin 40,000
units subcutaneously weekly on 04/15/2005 for his anemia in
addition to intermittent platelets transfusion averaging once a
month for his thrombocytopenia.
He continued erythropoietin treatment until developing neu-
tropenia with ANC of 0.7109/L in August 2007; a repeated bone
marrow biopsy and aspirate showed refractory anemia with excess
of blasts-2 with 60% cellularity and 11% blasts. He was enrolled on
protocol PH-93406 consisting of 5-azacitidine 75 mg/m2 for seven
days with or without AMG 531 (Romiplostim) on 28-day cycle
starting his ﬁrst on 09/01/2007 (he was randomized to both
agents). He received a total of 15 courses of both 5-azacitidine
and AMG 531 until the study closed in 12/09/2008. Six months
into the study, he was noted to have circulating blasts in the
peripheral blood for which he was evaluated for allogeneic stem
cell transplant. As he was deemed ineligible to transplant, the
study drugs were continued In spite of intermittently noticing
circulating blasts ranging between 2 and 7%. The occasional
peripheral blood blasts could be explained by the effect of
Romiplostim.6 These blasts did not correlate with the ﬁndings on
the repeated bone marrow biopsy and even at the end of study
biopsy (12/19/2008) that showed persistent MDS with 40% cellu-
larity and only 2% blasts. Due to closure of the study, his therapy
was changed to 5-azacitidine 75 mg/m2 for ﬁve days on 28-day
cycle; ﬁrst dose received on 01/02/2009. He ﬁnished 9 cycles by
10/17/2009 with worsening of transfusion requirement (up to
twice a week, with Hgb ranges 7.0–8.5 g/dL and platelets count
between 10 and 20109/L) and worsening neutropenia (ANC
0.5–0.7109/L).
The patient was enrolled on protocol I-144208 consisting of
low dose clofarabine 1 mg (ﬁxed dose) orally daily for ﬁve days on
28-day cycle. His baseline bone marrow aspirate and biopsy on 11/
19/2009 was consistent with persistent MDS with 70% cellularity
and 3% blasts. His ﬁrst cycle was complicated by a one-week
admission for neutropenic fever with negative bacterial cultures.
After two more cycles (March 2010) he had an episode of
Staphylococcus Epidermis and Serratia Liquefaciens bacteremia
that was successfully treated with IV antibiotics. His treatment
continued for a total of 32 cycles by the time of this report,
complicated by grade I transaminitis and grade I rash on lower
extremities. He continues to be transfusion-dependent, receiving
platelets on average once a week and red blood cells once or twice
a month. He has reasonable quality of life and functional capacity
with estimated Karnofsky score of 70%.To the best of our knowledge, only one other group7 studied
low-dose protracted oral clofarabine in MDS patients who failed
hypomethylating agents. They studied 5 mg (ﬁxed dose) daily for
10 consecutive days of a 28-day cycle. All patients who were
treated for 10 days had a greater than 25% drop in their baseline
counts with cycle one and received only seven days of treatment
in subsequent cycles. The protocol was then modiﬁed to admin-
ister clofarabine for seven days which did not result in any
signiﬁcant toxicity. That study was prematurely terminated by
the company after 19 patients were enrolled.
This case demonstrates the potential of using protracted low-
dose oral clofarabine in patients who failed hypomethylating
agents, a group of patients with extremely poor outcome.2,3 We
therefore propose that protracted low-dose oral clofarabine be
studied in this patient population.Contributions
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